NetworkNewsBreaks – Therma Bright Inc.’s (TSX.
Post# of 62
(Total Views: 470)
Posted On: 09/04/2019 4:17:23 PM
NetworkNewsBreaks – Therma Bright Inc.’s (TSX.V: THRM) (OTC: THRBF) TherOZap(TM) Technology Proven Successful at Inhibiting Zika Virus During In-Vitro Tests
Medical device technology provider Therma Bright (TSX.V: THRM) (OTC: THRBF) this morning announced that its TherOZap(TM) Technology has been proven successful at inhibiting the Zika virus during in-vitro tests. According to the update, Therma engaged a top Virology Research Laboratory in Canada to study the ability of its TherOZap(TM) technology to inactivate live Zika virus in culture media and to determine inhibition of the Zika virus infection in-vitro in selected cell cultures. Study researchers stated that, “the in-vitro testing has shown that a short heat pulse from the TherOZap(TM) device dramatically inhibits the production of infectious Zika virus in multiple cell types.” The results demonstrated that TherOZap(TM), which utilizes specialized materials, coatings and heat, was able to limit Zika virus (“ZIKV”) cell culture replication. “We are extremely pleased with the test results of our patent pending TherOZap(TM) technology to inhibit the Zika virus,” Therma Bright CEO Rob Fia said in the news release. “We look forward to testing our technology further and to potentially investigate other applications of the TherOZap(TM) technology against other mosquito borne diseases. We will identify partners to work with in these new indications and will seek non-dilutive funding to help fund the research in these new areas.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Medical device technology provider Therma Bright (TSX.V: THRM) (OTC: THRBF) this morning announced that its TherOZap(TM) Technology has been proven successful at inhibiting the Zika virus during in-vitro tests. According to the update, Therma engaged a top Virology Research Laboratory in Canada to study the ability of its TherOZap(TM) technology to inactivate live Zika virus in culture media and to determine inhibition of the Zika virus infection in-vitro in selected cell cultures. Study researchers stated that, “the in-vitro testing has shown that a short heat pulse from the TherOZap(TM) device dramatically inhibits the production of infectious Zika virus in multiple cell types.” The results demonstrated that TherOZap(TM), which utilizes specialized materials, coatings and heat, was able to limit Zika virus (“ZIKV”) cell culture replication. “We are extremely pleased with the test results of our patent pending TherOZap(TM) technology to inhibit the Zika virus,” Therma Bright CEO Rob Fia said in the news release. “We look forward to testing our technology further and to potentially investigate other applications of the TherOZap(TM) technology against other mosquito borne diseases. We will identify partners to work with in these new indications and will seek non-dilutive funding to help fund the research in these new areas.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)